Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking
2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals
3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers
4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Infectious Vaccines deals by company A-Z
Appendix 2 - Infectious Vaccines deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Infectious Vaccines deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

Appendix 4 - Infectious Vaccines deals by therapy area
Appendix 5 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures
Figure 1: Infectious Vaccines partnering since 2014
Figure 2: Active Infectious Vaccines dealmaking activity since 2014
Figure 3: Infectious Vaccines partnering by deal type since 2014
Figure 4: Infectious Vaccines partnering by disease type since 2014
Figure 5: Infectious Vaccines deals with a headline value
Figure 6: Infectious Vaccines deals with an upfront value
Figure 7: Infectious Vaccines deals with a milestone value
Figure 8: Infectious Vaccines deals with a royalty rate value
Figure 9: Top Infectious Vaccines deals by value since 2014
Figure 10: Most active Infectious Vaccines dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Companies mentioned
2A, A*STAR' Institute of Molecular and Cell Biology, ABEC, ABIVAX, ABL Bio, Abnova, Academy of Military Medical Sciences (China), Adaptive Phage Therapeutics, AdaptVac, Adjuvance Technologies, Aduro BioTech, Advaccine Biotechnology, Advanced Biological Laboratories, Advanced BioNutrition, Advent International, Aelix Therapeutics, Aeras, Aethlon Medical, Affinivax, AGC Biologics, Agenus Bio, AIM ImmunoTech, Akers Biosciences, Akshaya Bio, Albany Molecular Research, Aldevron, Algenex, Altimmune, American Gene Technologies, Amyris, AnGes MG, Antigen Discovery, Antitope, Appili Therapeutics, Applied DNA Sciences, Aptimmune Biologics, Aragen Bioscience, Arcturus Therapeutics, Ardigen, Aridis Pharmaceuticals, Ark Animal Health, Artes Biotechnology, Astellas Pharma, AstraZeneca, Avanzcare, Avid Bioservices, Batavia Biosciences, Battelle, Bavarian Nordic, Baxter International, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, Beth Israel Deaconess Medical Center, Bharat Biotech, Bill and Melinda Gates Foundation, Binex, Bintai Kinden, BioClones, BioComo, bioCSL, Biofactura, Bio Farma, Biokinetic Europe, Biomedical Advanced Research and Development Authority, BiondVax, BioNTech, BioSun Pharmed, Biothera Pharmaceuticals, Blue Water Vaccines, Boehringer Ingelheim, Bpifrance, BravoVax, Brickell Biotech, Brighton Biotech, Broad Institute, BTG, Burnet Institute, Butantan Institute, Caliber Biotherapeutics, California Institute for Medical Researc, Calixar, CARB-X, Catalent, Celonic, Center for Genetic Engineering and Biotechnology (Cuba), Centers for Disease Control and Prevention, Cevec Pharmaceuticals, Changchun BCHT Biotechnology, Children's Hospital Boston, Chimeron Bio, China National Biotech Group (CNBG), Cilian, CimCure, CiToxLAB, City College of New York, City of Hope, ClearPath, Clover Biopharmaceuticals, CMC Biologics, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Codagenix, Codiak BioSciences, ContraFect, Corden Pharma, Corgenix Medical, Create Vaccine Company, Crozet BioPharma, Crucell, CryoPort, CSIRO, CSL, CureVac, CVC, Cystron Biotech, Cytiva, Cytovance Biologics, d3 Medicine, Daiichi Sankyo, Dalton Pharma Services, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Department of Defense, Department of Health and Human Services, Diavax Biosciences, Diaxonhit, Dr. Reddy's Laboratories, Duke-NUS Graduate Medical School Singapore, Duke University, Dyadic International, Dynavax Technologies, DynPort Vaccine Company, Eddingpharm, Eli Lilly, Emergent BioSolutions, Emergex Vaccines, Emmes, Emory University, Endo International, Enesi Pharma, Engility, Ennaid Therapeutics, Entos Pharmaceuticals, Epivax, EpiVax Therapeutics, Etna Biotech, Etubics, Evaxion Biotech, EVQLV, Excivion, ExpreS2ion Biotechnologies, Farmacore Biotechnology, Fatro, Federal Ministry of Education and Research (BMBF), Fina Biosolutions, Finlay Institute, Flow Pharma, FluGen, Fortress Biotech, Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Fujifilm, Fujifilm Diosynth Biotechnologies, GAVI Alliance, GC Pharma, GE Healthcare, GeneOne Life Science, Generex Biotechnology, Genetic Immunity, Geneva Foundation, Genexine, Genkyotex, Genocea Biosciences, Genticel, GenVec, George Mason University, Georgia State University Research Foundation (GSURF), Georgia Tech Research Corporation, GeoVax, German Cancer Research Center, German Federal Ministry of Education and Research, German Government, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glide Technologies, Global Health Innovative Technology Fund (GHIT), Government of Canada, Government of France, Government of Israel, Government of Netherlands, Grameen Health, Grand River Aseptic Manufacturing, Guangzhou Institute of Respiratory Disease, Halix, HaloVax, HanaVax, Harro Hofliger, Harvard Medical School, Harvard University, Hawaii Biotech, Healthcare Royalty Partners, Health Decisions, Heat Biologics, HemispheRx Biopharma, Henry M. Jackson Foundation, Horizon 2020, Hoth Therapeutics, Howard Hughes Medical Institute (HHMI), Human Vaccines Project, hVIVO, iBio, IBT Bioservices, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, IDT Biologika, IHI, ILiAD Biotechnologies, Illumina, ImmBio, Immune Design, Immune Targeting Systems, ImmunityBio, Immunomic, ImmunoPrecise Antibodies, Immunotech Laboratories, Immunovaccine, Immuron, Imperial College London, Imutex, Indian Council of Medical Research, Infectious Disease Research Institute (IDRI), InnaVirVax, Innovate UK, Innovative Medicines Initiative (IMI), Innovo, Inovio, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Institute for Bioscience and Biotechnology Research, Institute of Biomedical Research, Institut Pasteur, Integral Molecular, Integrated BioTherapeutics, International AIDS Vaccine Initiative, International Medica Foundation, International Vaccine Institute (IVI), Intravacc, Ippox Foundation, IQVIA, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Israel Investment Center, Italian Government, Janssen Biotech, Janssen Pharmaceuticals, Jenner Institute, Johnson & Johnson, JSC Pharmadis, KAI Research, Kalon Biotherapeutics, Kansas State University, Karolinska Institute, Kemin Industries, Kindred Bio, King Saud University, Kleo Pharmaceuticals, Korea Advanced Institute of Science and Technology, Laboratorios Farmaceuticos Rovi, Laboratorios Liomont, Laboratory of Malaria Immunology and Vaccinology (LMIV), La Jolla Institute for Allergy & Immunology, Laxisam, Leiden University, Leidos, Leukocare, LiteVax, Lonza, Los Angeles Biomedical Research Institute, Louisiana State University, Lumos Pharma, Lund University, Massachusetts General Hospital, Massachusetts Life Sciences Center, Matrivax, McKesson, Medicago, Medical University of Vienna, MediciNova, MediGene, Medigen Vaccine Biologics, MedImmune, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Meridian Life Science, Metaclipse Therapeutics, Mexican National Technology and Science Council, Micron Biomedical, Midatech, Mie University, MilliporeSigma, MinervaX, Ministry of Finance (China), Ministry of Health, Ministry of Health (Israel), Ministry of Health, Labor and Welfare, Ministry of Industry and Information Technology, MMS, Moderna Therapeutics, MSD Wellcome Trust Hilleman Laboratories, Mucosis, Mundo Sano, MyLife Technologies, Mymetics, Myriad RBM, Mytide Therapeutics, NanoBio, NanoPass Technologies, Nanotherapeutics, NantKwest, National Cancer Institute, National Development and Reform Commission, National Health and Family Planning Commission, National Health Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Innovation, National Institute of Cholera and Enteric Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Hygiene and Epidemiology, National Institute of Infectious Diseases, National Institute of Vaccines and Medical Biologicals, National Institutes of Health, National Research Council Canada, National Research Council Industrial Research Assistance Program, National Research Council of Canada, Naval Medical Research Center, New Zealand's Foundation for Research, Science and Technology, Noachis Terra, Noble Life Sciences, NovaDigm Therapeutics, Novartis, Novavax, Novo, Oberland Capital, Ohio State University, Ology Bioservices, Oragenics, Organic Vaccines, OSE Immunotherapeutics, Osivax, Oswaldo Cruz Foundation (Fiocruz), Oxgene, Pacific GeneTech, Panacea Biotech, Partnership for Influenza Vaccine Introduction, PATH (Appropriate Technology in Health), PATH Malaria Vaccine Initiative, PaxVax, PDS Biotechnology, PepTcell, Perelman School of Medicine, Pevion, Pfenex, Pfizer, Pharco Pharma, Pharm-Olam International, PharmaJet, Pharma Science, PharmAthene, PnuVax, Pohang University Of Science And Technology, PolyPeptide Group, PPD, Precision NanoSystems, Precision Virologics, Premas Biotech, Probiomed, Profectus Biosciences, Prokarium, Protein Sciences, PT Bio Farma, Public Health Agency of Canada, Public Health England, Public Health Vaccines, Qualtran, Quebec Government, Ragon Institute, Rapid Micro Biosystems, Recipharm, Redbiotec, Refana, ReiThera, Rockefeller University, RSV, Russian Direct Investment Fund, Sabin Vaccine Institute, SAB Therapeutics, Saiba, Sanaria, Sanofi, Sanofi-Pasteur, Sartorius, Scancell, Science 37, Scripps Research Institute, Seattle Biomed, Seattle Children's Hospital, SEEK, Selecta Biosciences, Selexis, Sementis, Seoul National University, Serum Institute of India, Shenzhen Kangtai Biological Products, Shionogi, Shionogi Pharma, Sinergium Biotech, Sinopharm Group Beijing HuaHong, Sinotek-Advocates International Industry Development, Sinovac Biotech, SiO2 Medical Products, SK Bioscience, SK Chemicals, Small Business Innovation Research, SmartPharm Therapeutics, Smiths Medical, Soligenix, Sorrento Therapeutics, Southern Research Institute, Spicona, SRI International, St. Jude Children's Research Hospital, Stanford University, Stellar Biotechnologies, Strategic Vaccines, Sunstone Capital, SutroVax, Symbiosis, Takara Bio, Takeda Pharmaceutical, Takis Biotech, Talem Therapeutics, Technical University of Denmark (DTU), TechnoVax, Texas A&M University, Texas Biomedical Research Institute, Texas Children's Hospital, TFF Pharmaceuticals, The International AIDS Vaccine Initiative, The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center, Themis Bioscience, The Native Antigen Company, Theraclone Sciences, Therapure Biopharma, Therapyx, Thomas Jefferson University, Tianjin CanSino Biotechnology, TONIX Pharmaceuticals, Translate Bio, Trellis Bioscience, Trianni, TriLink BioTechnologies, Trinity Pharmaceuticals, Truffle Capital, Tulane University, UK Government, Uldic Investment, UMN Pharma, United Nations Children Fund, United States Agency for International Development, Univercells, University of Adelaide, University of Alabama at Birmingham, University of Alberta, University of California, Davis, University of California, San Diego, University of California Berkeley, University of Chicago, University of Copenhagen, University of Edinburgh, University of Georgia, University of Guelph, University of Hawaii, University of Maryland, University of Maryland School of Medicine, University of Massachusetts, University of Miami, University of Miami Miller School of Medicine, University of Montreal, University of Nagasaki, University of Nebraska, University of Oxford, University of Pennsylvania, University of Queensland, University of Saskatchewan, University of Southampton, University of Texas, University of the Witwatersrand, University of Tokyo, University of Toronto, University of Tubingen, University of Washington, University of Wisconsin-Madison, US Army, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, US Department of Agriculture, US Government, Utrecht University, Vaccitech, Valera Pharmaceutical, Valneva, Variation Biotechnologies, Vaxart, Vaxeal, Vaxess Technologies, Vaxil BioTherapeutics, VaxNewMo, Vaxxas, VBI Vaccines, Verndari, Versatope Therapeutics, Vibalogics, Vical, Vigene Biosciences, Viral Hemorrhagic Fever Consortium, Viravaxx, Vir Biotechnology, Viroclinics Biosciences, VirPath, Vivaldi Biosciences, ViveBio, VLP Therapeutics, Voltron Therapeutics, Wageningen University, Walter Reed Army Institute of Research, Washington University in St Louis, WCCT Global, Wellcome Trust, Wistar Institute, World Health Organization, WuXi Biologics, Xenetic Biosciences, Yisheng Biopharma, Zoetis, Zolovax, Zuellig Pharma China, Zydus Cadila, ZYUS Life Sciences